LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

LLY

1,149.75

+1.21%↑

JNJ

234.38

+2.98%↑

ABBV

230.13

+3.42%↑

UNH

400.89

+1.11%↑

MRK

123.39

+3.57%↑

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Deschisă

SectorSănătate

71.14 -0.63

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

70.67

Maxim

72.07

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	23.909 49.888
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+19.83% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	432M 8.1B
Deschiderea anterioară	71.77
Închiderea anterioară	71.14

Sentimentul știrilor

By Acuity

38%

62%

110 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 iun. 2026, 21:51 UTC

Principalele dinamici ale pieței

Merlin Shares Rally After Defense Department's Design Review Wraps

4 iun. 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 iun. 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 iun. 2026, 23:42 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 iun. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Energy Resources of Australia to Enter Trading Halt

4 iun. 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 iun. 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 iun. 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 iun. 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 20:44 UTC

Achiziții, Fuziuni, Preluări

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 iun. 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 iun. 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 iun. 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 iun. 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 iun. 2026, 18:47 UTC

Achiziții, Fuziuni, Preluări

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 iun. 2026, 18:38 UTC

Câștiguri

Money Quote: Tech Weakness in Context -- WSJ

4 iun. 2026, 18:24 UTC

Câștiguri

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 iun. 2026, 16:58 UTC

Câștiguri

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 iun. 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 iun. 2026, 16:38 UTC

Câștiguri

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 iun. 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 iun. 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 iun. 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 iun. 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

19.83% sus

Prognoză pe 12 luni

Medie 85.8 USD 19.83%

Maxim 96 USD

Minim 70 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

110 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.